Immunicum AB: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Immunicum completes private placement and resolves rights issue bringing about SEK 100 mln
Immunicum AB:Completes private placement of 3,500,000 shares at a price of 16.00 Swedish crowns.Says has raised in total 56 million Swedish crowns before issue costs.Says the issue was directed towards a group of qualified Swedish and international investors.Resolves rights issue of new shares, raising a maximum of 44,080,000 crowns.Offers up to 2,755,000 new shares.Says five existing shares entitle the holder to subscribe for one new share.Sets subscription price at 16.00 crowns per share, which corresponds to the price in the private placement.Subscription period runs May 14-28.Says the rights issue is fully underwritten.The share issues will together bring Immunicum gross proceeds of about 100 million Swedish crowns.
Latest Developments for Immunicum AB
- Immunicum AB presents updated survival results for Intuvax-treated renal cancer patients
- Immunicum reports preliminary regression data after add-on therapy with tyrosine kinase inhibitors and continued compelling survival data from phase I/II-study in renal cell carcinoma
- Immunicum AB submits final report for phase I/II trial in metastatic renal cell carcinoma showing positive safety data and promising survival data
- Immunicum AB reports promising preclinical results for its CD70 technology in adoptive immunotherapy
Latest Key Developments in Biotechnology
- Neurocrine Biosciences Inc receives breakthrough therapy designation for NBI-98854 in Tardive Dyskinesia
- Acorda Therapeutics Inc raises FY 2014 AMPYRA net revenue outlook
- Quintiles Transnational Holdings Inc raises FY 2014 EPS guidance
- Chiome Bioscience Inc amends consolidated full-year outlook for FY 2014
- Share this
- Digg this